Live feed07:00:00·53mPRReleasevia QuantisnowEnanta Pharmaceuticals to Present Data for Zelicapavir, an Oral, Once-Daily, N-Protein Inhibitor, in Development for the Treatment of Respiratory Syncytial Virus, at IDWeek™ 2026ByQuantisnow·Wall Street's wire, on your screen.ENTA· Enanta Pharmaceuticals Inc.Health Care
